ALK (ALKB:DC / OMX: ALK B) today announced that real-world evidence evaluating the clinical performance of the nasal adrenaline spray neffy® in US patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy has been accepted for scientific publication. The findings represent the first large-scale analysis of treatment outcomes with neffy® during routine clinical practice and were accepted for publishing as a correspondence in the Annals of Allergy, Asthma and Immunology, ...